Patents by Inventor Marie Bouillie

Marie Bouillie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for determining the risk of acute graft versus host disease
    Patent number: 10151745
    Abstract: The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(?) iNKT cell sub-population. In particular, CD3+CD4? TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: December 11, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Assistance Publique—Hopitaux de Paris, Universite Paris Descartes, Imagine Institut des Maladies Genetiques Necker Enfants Malades
    Inventors: Olivier Hermine, Marie Thérèse Rubio, Marie Bouillie, Maria Leite de Maraes
  • METHODS FOR DETERMINING THE RISK OF ACUTE GRAFT VERSUS HOST DISEASE
    Publication number: 20150301022
    Abstract: The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(?) iNKT cell sub-population. In particular, CD3+CD4? TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.
    Type: Application
    Filed: November 21, 2013
    Publication date: October 22, 2015
    Applicants: Assistance Publique - Hopitaux de Paris, Université Paris Descartes, Imagine Institut des Maladies Genetiques Necker Enfants Malades
    Inventors: Olivier Hermine, Marie Thèrèse Rubio, Marie Bouillie, Maria Leite de Maraes